REGENXBIO, Inc. (RGNX)
5.72
-0.52
(-8.41%)
USD |
NASDAQ |
May 15, 16:00
5.83
+0.11
(+1.92%)
After-Hours: 20:00
REGENXBIO EPS Diluted (Quarterly) : -1.718 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Sarepta Therapeutics, Inc. | 2.878 |
| Ocugen, Inc. | -0.0586 |
| Replimune Group, Inc. | -0.7694 |
| AbbVie, Inc. | 0.3861 |
| Krystal Biotech, Inc. | 1.833 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -90.05M |
| Revenue (Quarterly) | 6.393M |
| Total Expenses (Quarterly) | 96.44M |
| Enterprise Value | 393.62M |
| Gross Profit Margin (Quarterly) | -133.6% |
| Profit Margin (Quarterly) | -1.41K% |
| Earnings Yield | -97.73% |
| Normalized Earnings Yield | -97.73 |